Status: Recruiting
Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab
This study is a multicenter, open-label, single-arm phase II clinical trial investigating the efficacy and safety of niraparib monotherapy maintenance in HRD-positive newly diagnosed advanced epithelial ovarian cancer (EOC), including primary peritoneal and/or fallopian tube tumors, following response to front-line chemotherapy in combination with bevacizumab. A total of 116 patients will be enrolled.
Participants needed: 116
Trial details
Phase: Phase 2Age: 18-75Biological sex: FemaleType: InterventionalSponsor: Peking University Cancer Hospital & InstituteUpdated: Oct 1, 2026Locations: 1
Eligibility criteria
The written informed consent form shall be signed before proceeding with any stu... [+11]
Histopathological types other than high-grade ovarian/tubal/peritoneal cancer or... [+5]